Replimune (REPL) Total Current Liabilities (2018 - 2025)
Replimune's (REPL) quarterly Total Current Liabilities came in at $50.1 million in Q4 2025, up 4.59% year-on-year from $47.9 million in Q4 2024, and down 5.32% quarter-over-quarter from $52.9 million in Q3 2025.
Replimune (REPL) Total Current Liabilities (2018 - 2025) Analysis & Trends
Replimune has disclosed Total Current Liabilities across 8 years of filings, most recently posting $50.1 million for Q4 2025.
- Total Current Liabilities for Q4 2025 came in at $50.1 million, up 4.59% year-over-year; the trailing twelve-month figure through Dec 2025 was $50.1 million (up 4.59% YoY), and the FY2025 annual result was $62.4 million, up 54.22% from the prior year.
- Total Current Liabilities came in at $50.1 million for Q4 2025 at Replimune, down from $52.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $62.4 million in Q1 2025 to a low of $14.5 million in Q1 2021.
- The 5-year median for Total Current Liabilities is $34.8 million (2023), against an average of $34.6 million.
- Across the five-year window, Total Current Liabilities soared 69.23% in 2023 and increased 4.59% in 2025, its largest moves.
- Replimune's Total Current Liabilities stood at $18.3 million in 2021, then surged by 44.68% to $26.5 million in 2022, then jumped by 46.05% to $38.6 million in 2023, then gained by 23.91% to $47.9 million in 2024, then climbed by 4.59% to $50.1 million in 2025.
- The last three Total Current Liabilities figures came in at $50.1 million (Q4 2025), $52.9 million (Q3 2025), and $59.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 13.42 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 72.86 Mn |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | 50.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 50.09 Mn |
| Sep 30, 2025 | 52.90 Mn |
| Jun 30, 2025 | 59.56 Mn |
| Mar 31, 2025 | 62.36 Mn |
| Dec 31, 2024 | 47.89 Mn |
| Sep 30, 2024 | 43.79 Mn |
| Jun 30, 2024 | 35.68 Mn |
| Mar 31, 2024 | 40.44 Mn |
| Dec 31, 2023 | 38.65 Mn |
| Sep 30, 2023 | 39.83 Mn |
| Jun 30, 2023 | 32.24 Mn |
| Mar 31, 2023 | 33.83 Mn |
| Dec 31, 2022 | 26.46 Mn |
| Sep 30, 2022 | 23.54 Mn |
| Jun 30, 2022 | 20.31 Mn |
| Mar 31, 2022 | 20.76 Mn |
| Dec 31, 2021 | 18.29 Mn |
| Sep 30, 2021 | 16.64 Mn |
| Jun 30, 2021 | 15.05 Mn |
| Mar 31, 2021 | 14.55 Mn |